The viscous drag (shear stress) provided by flowing blood exerts a potent atheroprotective effect (16) . This is evidenced by the finding that atherosclerotic lesions preferentially develop in areas with low or turbulent flow, whereas regions with uniform laminar flow are protected (2, 17) . The endothelial lining is the primary sensor of wall shear stresses, and functions as a transducer of these biomechanical stimuli into biological responses within the vessel wall (2, 18, 19) . Therefore, we hypothesized that shear stress might interfere with CD40-mediated endothelial cell activation. We demonstrate that shear stress blocks the proinflammatory and procoagulatory activity of CD40L. Because CD40 signaling is regulated by TRAFs, we further investigated the influence of shear stress on TRAF proteins. We identified TRAF-3 upregulation as an inhibitory mechanism that abrogates CD40 signaling in endothelial cells.
Atherosclerosis is an inflammatory disease of large arteries that is initiated through the activation of endothelium by proinflammatory mediators. CD40 receptor stimulation has been implicated in the pathogenesis of atherosclerosis. One of the most important atheroprotective stimuli is the viscous drag (shear stress) generated by the streaming blood acting on the endothelial monolayer. Here, we demonstrate that shear stress prevents CD40 ligand-induced endothelial cell activation, and we identify upregulation of TNF receptor-associated factor-3 (TRAF-3) as a potent CD40-inhibitory mechanism. Shear stress specifically upregulates TRAF-3 in cultured endothelial cells. Moreover, in the endothelial cells overlying human atherosclerotic plaques, TRAF-3 expression is upregulated in areas with high shear stress. Overexpression of TRAF-3 inhibits endothelial expression of proinflammatory cytokines and tissue factor and blocks DNA-binding activity of the transcription factor AP-1; it thereby prevents CD40-induced endothelial activation. Thus, upregulation of TRAF-3 represents a novel mechanism for preserving the functional integrity of the endothelial monolayer.
tle, Washington, USA). Nordihydroguaiaretic acid (NDGA), pyrolidine dithiocarbamate (PDTC), and curcumin were purchased from Sigma-Aldrich (Taufkirchen, Germany). IL-8 release was detected in cell culture supernatants by Quantikine immunoassay (R&D Systems Inc., Wiesbaden, Germany). Tissue factor activity was measured with a clotting assay as described previously (21) .
For Western blotting, HUVEC homogenates were obtained as described previously (20) , and blots were incubated with the following antibodies: TRAF-2, TRAF-3, TRAF-5, CD40, IκBα, topoisomerase I (Santa Cruz Biotechnology Inc., Santa Cruz, California, USA), actin (Chemicon International, Hofheim, Germany), ERK1/2, phospho-ERK1/2, phospho-JNK (Cell Signaling Technology Inc., Beverly, Massachusetts, USA), and phosphoJun (Upstate Biotechnology Inc., Lake Placid, New York, USA). To immunoprecipitate the CD40 receptor, cells were incubated overnight at 4°C with an antibody against CD40 (Upstate Biotechnology Inc.). After incubation with protein A/G agarose beads (30 µl/mg protein; Santa Cruz Biotechnology Inc.) for 1.5 hours at 4°C, the protein complexes were washed and analyzed for TRAF-3 binding by Western blot. For nuclear and cytoplasmic separation, Nuclear and Cytoplasmic Extraction Reagents were used according to the instructions of the manufacturer (Pierce Chemical Co., Rockford, Illinois, USA).
Northern blot analysis and RNase protection assay. Northern blots were performed as previously described (22) . TRAF-3 mRNA expression was analyzed with the ribonuclease protection assay using the multiprobe template set hAPO-5 according to the instructions of the manufacturer (PharMingen, San Diego, California, USA).
Platelet preparation and activation. The platelet-rich plasma obtained from healthy human subjects was collected into an equal volume of acid-citrate-dextrose buffer (38 mM citric acid, 75 mM trisodium citrate, 124 mM glucose; pH 4.5) and centrifuged at 700 g for 10 minutes. Platelets were resuspended in Tyrode's/HEPES buffer (1.8 mM CaCl 2 , 2.7 mM KCl, 0.5 mM MgCl 2 , 137 mM NaCl, 10 mM HEPES, 0.36 mM NaH 2 PO 4 , 5 mM glucose; pH 7.35), and centrifuged at 700 g for 10 minutes. After resuspension, 1.5 × 10 8 platelets were incubated with HUVECs, and activated with 0.2 U/ml human thrombin (Boehringer Mannheim GmbH, Mannheim, Germany). Cell culture dishes were centrifuged at 700 g for 2 minutes, and thrombin was neutralized after 5 minutes with 2 U/ml hirudin (Boehringer Mannheim GmbH).
Plasmid transfection. Plasmid encoding the human fulllength TRAF-3 was kindly donated by J. Reed (Burnham Institute, La Jolla, California, USA). The dominant-negative construct (amino acids 340-568) (23) was subcloned by PCR in pcDNA3.1-Myc-His (Invitrogen BV, Groningen, The Netherlands). Human full-length TRAF-2-and TRAF-5-encoding plasmids were kindly donated by S. Lederman (Department of Medicine, Columbia University, New York, New York, USA) (24) , and were subcloned in pcDNA3.1-Myc-His. Clones with verified sequences were transfected in HUVECs (3.5 × 10 5 cells/6-cm well; 3 µg plasmid DNA; 25 µl SuperFect) (Qiagen, Hilden, Germany), with a transfection efficiency of about 50%, as previously described (20) .
Transfection with decoy oligonucleotides. Phosphorothioate double-stranded decoy oligonucleotides (1 µg) corresponding to the AP-1 binding sequence (5′-AGCTTGT-GAGTCAGAAGCT-3′) or scrambled sequence (5′-TTGC-
Figure 1
Shear stress prevents CD40L-induced endothelial cell activation. HUVECs were preexposed to shear stress for 12 hours before stimulation with recombinant CD40L for 6 hours under continuous flow conditions. MCP-1 mRNA expression was monitored by Northern blot analysis as representatively shown (a). The quantification is shown in (b); data are mean ± SEM. n = 4, *P < 0.05 vs. CD40L stimulation. (c) Shear stress inhibits CD40-induced tissue factor activity. After preexposure of HUVECs to shear stress, tissue factor activity was detected using a clotting assay. Data are mean ± SEM. n = 4, *P < 0.05 vs. CD40L stimulation. (d) Platelets were activated as described in Methods and incubated with HUVECs that had been preexposed to shear stress for 12 hours. MCP-1 expression was detected after 6 hours of coincubation. A representative Northern blot is shown. Quantification was performed with four experiments. P < 0.05 vs. activated platelets. TF, tissue factor. CGTACCTGACTTAGC-3′) were incubated in 100 µl RPMI medium in the presence of 5 µl LipofectAMINE (Life Technologies Inc., Karlsruhe, Germany) for 30 minutes at room temperature. HUVECs (4.0 × 10 5 cells) were washed with RPMI and incubated with 2 ml RPMI before adding the LipofectAMINE/oligonucleotide mixture. After 5 hours of further incubation, 3 ml complete endothelial basal medium was added.
Immunostaining and immunohistochemistry. HUVECs were washed, fixed with 2% paraformaldehyde, and stained with antibodies against TRAF-2, TRAF-3, or TRAF-5 (1:50 in PBS/5% FCS; Santa Cruz Biotechnology Inc.). Cells were incubated with a secondary anti-rabbit antibody linked to FITC (1:20 in PBS/5% FCS; DAKO Corp., Hamburg, Germany), followed by counterstaining with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI; 1 µg/ml). Immunohistochemistry of human atherosclerotic plaques derived by endarterectomy from nine patients with coronary artery disease was performed with a TRAF-3 antibody (Santa Cruz Biotechnology Inc.). Semiquantitative examination was performed by two blinded investigators.
Electrophoretic mobility shift assay. Nuclear extracts from HUVECs were prepared with Nuclear and Cytoplasmic Extraction Reagents according to the manufacturer's instructions (Pierce Chemical Co., Rockford, Illinois, USA). The double-stranded gel shift oligonucleotides (Santa Cruz Biotechnology Inc.) for AP-1 (5′-CGCTTGATGACTCAGCCGGAA-3′) were end-labeled with [γ-32 P]ATP. Nuclear extracts (5 µg) were incubated in binding buffer with 1.5 µg of poly(dI-dC), 1 mM DTT, and 32 P-labeled oligonucleotide probe (0.5 ng) for 30 minutes at room temperature, and analyzed by electrophoretic mobility shift assay (EMSA) using a nondenaturing 5% polyacrylamide gel. The specificity of binding was examined by competition with unlabeled AP-1 and AP-1 mutant oligonucleotides (5′-CGCTTGAT-GACTTGGCCGGAA-3′), respectively. Supershift analysis was performed with 4 µg of AP-1 Supershift antibody (Santa Cruz Biotechnology Inc.).
Results

Shear stress inhibits CD40-induced endothelial activation.
To investigate the effect of shear stress on CD40-induced endothelial activation, HUVECs were exposed to shear stress before stimulation with recombinant CD40L. The proinflammatory response of endothelial cells was determined by measuring the expression of the proinflammatory chemoattractant protein MCP-1 and the procoagulant tissue factor activity. As shown in Figure 1 , a and b, preexposure to shear stress completely prevented CD40-induced endothelial MCP-1 expression. Moreover, CD40L-induced tissue factor activity, which promotes thrombus formation, was significantly reduced by preexposure of the endothelial cells to laminar flow (Figure 1c) .
Under pathophysiological conditions, activated platelets may serve as the stimulus for activation of the CD40 receptor in endothelial cells (25) . Therefore, we performed analyses to determine whether shear stress may also protect against the proinflammatory effect induced by activated platelets. As illustrated in Figure 1d , activated platelets potently stimulated the expression of MCP-1, which was significantly reduced in HUVECs preexposed to shear stress (respective fold increase: 2.3 ± 0.3 vs. 3.0 ± 0.2, P < 0.05). The inhibitory effect of shear stress in this model is essentially identical to that achieved by neutralizing anti-CD40 antibodies (25) . The lack of complete inhibition most likely reflects stimulation of various signaling pathways by activated platelets. A similar inhibitory effect of shear stress was achieved when platelet-induced tissue factor expression was measured (data not shown). Taken together, these data show that shear stress exposure prevents CD40 signaling induced by either recombinant CD40L or by activated platelets, and thereby inhibits the proinflammatory and prothrombotic response of endothelial cells to CD40 activation.
Shear stress upregulates TRAF-3 expression in vitro and in vivo. Having demonstrated that shear stress prevents CD40L-induced endothelial cell activation, we attempted to characterize the underlying molecular mechanism. The intracellular signaling of CD40 is regulated by a family of cytoplasmic adapter proteins, the TRAFs. Whereas most TRAFs, including TRAF-2 and TRAF-5, promote intracellular signal transduction, TRAF-3 inhibits CD40 signaling by an unknown mechanism (14, 15, (26) (27) (28) . Therefore, we examined the regulation of TRAF-2, TRAF-3, and TRAF-5 by shear stress. Shear stress timeand dose-dependently upregulates TRAF-3 mRNA and protein expression (Figure 2 , a-c), whereas TRAF-2 and TRAF-5 protein expression remain unchanged upon application of shear stress (Figure 2d ). Determination of TRAF-3 transcription by nuclear runon assays did not reveal any effect by shear stress (control: 104% ± 14%; shear stress: 114% ± 18% compared with GAPDH). Expression of the CD40 receptor was not altered by shear stress, excluding the possibility that shear stress inhibits CD40 signaling by receptor downregulation (Figure 2e ). These data suggest that shear stress interferes with CD40 signaling via specific upregulation of the inhibitory protein TRAF-3.
Next, we examined whether shear stress also affects TRAF-3 expression in vivo, by performing TRAF-3 immunostaining in human atherosclerotic plaques. As shown in Figure  2f , endothelial TRAF-3 expression is specifically upregulated in the area upstream and within the maximal stenosis ("upstream part of the plaque"), which is characterized by high shear stress. In contrast, in areas distal to the maximal stenosis ("downstream part of the plaque"), where flow is unsteady or turbulent, only very weak staining or no staining was detected (Figure 2f ). Semiquantitative grading of the immunohistochemical staining from 0 (absence of staining) to 4 (maximal staining) revealed significantly increased expression of TRAF-3 in the upstream area with high shear stress (2.56 ± 0.22) compared with the downstream part of the lesions (1.4 ± 0.4, n = 9, P = 0.0045). Taken together, our data illustrate that the level of shear stress determines the expression of TRAF-3 in endothelial cells in vitro and in vivo.
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TRAF-3 blocks CD40-induced endothelial cell activation.
In order to examine a causal role for TRAF-3 in modulation of endothelial cell activation, the effect of overexpressed TRAF-3 on CD40-stimulated endothelial cell activation was determined. TRAF-3 expression abrogated CD40-triggered MCP-1 expression and IL-8 release (Figure 3, a and b) . Moreover, CD40L-stimulated tissue factor activity was significantly reduced by TRAF-3 overexpression (Figure 3c ), clearly demonstrating that TRAF-3 is sufficient to inhibit CD40 signaling. To address the contribution of TRAF-3 to the inhibitory effect of shear stress, endothelial cells were transfected with a dominant-negative TRAF-3 construct (23) . Dominant-negative TRAF-3 partially reversed the inhibitory effect of shear stress on CD40L-induced MCP-1 expression (261% ± 33% vs. 152% ± 14%, n = 4, P < 0.05; Figure 3d ), thus demonstrating that shear stress requires TRAF-3 upregulation to prevent CD40-induced endothelial activation. However, the incomplete inhibition suggests that shear stress exerts additional CD40 inhibitory effects that are independent of TRAF-3.
TRAF-3 inhibits AP-1 DNA binding. Next, we investigated the mechanism by which TRAF-3 interferes with CD40 signaling. Whereas expression of MCP-1 and proinflammatory cytokines was shown to be mainly attributed to activation of the transcription factors NF-κB and AP-1 (12), the distinct contribution of these transcription factors to CD40L-induced endothelial cell activation is less clear. Therefore, we first identified the transcription factor that mediates CD40L-induced MCP-1 expression in endothelial cells. As shown in Figure 4 , CD40L-induced MCP-1 expression was blocked by pharmacological inhibitors of AP-1 such as NDGA or curcumin (Figure 4a ), or by transfection of the cells with AP-1 decoy oligonucleotides (Figure 4b ). In contrast, inhibition of NF-κB by PDTC did not affect CD40L-induced MCP-1 expression (Figure 4c) . Moreover, CD40L stimulation did not alter the degradation of the NF-κB inhibitor IκBα (Figure 4d ). These data indicate that AP-1, but not NF-κB, mediates CD40L-induced MCP-1 expression in endothelial cells.
To elucidate the target of TRAF-3, we further investigated the effect of TRAF-3 expression on the downstream signaling pathway mediating CD40L-induced AP-1 activation. Activation of AP-1 requires homo-or heterodimer formation of Jun and Fos (29) . Indeed, CD40L stimulated phosphorylation of JNK, the JNK substrate c-Jun, and ERK1/2 ( Figure 5, a and b) . However, TRAF-3 overexpression did not affect CD40L-induced activation of the JNK-ERK1/2 pathway ( Figure  5, a and b) . Consistent with this finding, coimmunoprecipitation studies revealed that TRAF-3 was not bound to the CD40 receptor (data not shown). Moreover, TRAF-3 was shown to localize mainly in the nuclei, as demonstrated by immunohistochemistry and biochemical fractionation, whereas the other members of the TRAF family such as TRAF-2 and TRAF-5 revealed different localization ( Figure 5, c and d) . Similarly, predominant nuclear localization of TRAF-3 was also shown in human dermal and cardiac microvascular endothelial cells (Figure 5d and data not shown), but not in NIH 3T3 cells (data not shown). These data suggest that TRAF-3 does not interfere with the proximal signal events, but acts downstream of Jun activation. Therefore, we tested the effect of TRAF-3 on CD40L-induced AP-1 activation using EMSA. As illustrated in Figure 5e , TRAF-3 overexpression prevents CD40L-induced AP-1 activation. In contrast, overexpression of TRAF-2 or TRAF-5 did not affect CD40L-stimulated AP-1 DNA binding activity (Figure 5e ). Controls with unlabeled oligonucleotides and supershift in the presence of AP-1 antibody are shown in Figure 5f .
Discussion
Our data demonstrate that shear stress upregulates mRNA and protein expression of TRAF-3. The sustained upregulation of TRAF-3 in the endothelial monolayer that is exposed to laminar shear stress prevents the proinflammatory and procoagulatory activation of endothelial cells in response to CD40L. Compelling evidence suggests that CD40 is a major trigger eliciting a proinflammatory reaction on endothelial cells, and that it plays an important role in the formation of athero- sclerotic lesions (9) . The inhibition of CD40 signaling occurs in areas of the endothelial lining exposed to laminar shear stress. These areas are characteristically associated with atherosclerotic lesion-protected arterial geometries in vivo. The inhibition of CD40 signaling thereby may represent a mechanism that would explain the well-known atheroprotective effects of shear stress.
Beyond the regulation of lesion development, CD40 also triggers procoagulatory effector pathways that are involved in thrombus formation. Indeed, CD40L is significantly elevated in patients with acute coronary syndromes (30) . Therefore, TRAF-3-mediated inhibition of tissue factor expression induced by CD40L or activated platelets may additionally limit the procoagulatory activity of the endothelium, which covers the vessel wall and the plaque surface.
Exposure of endothelial cells to shear stress exerts profound effects on endothelial cell morphology and function. These effects are mediated by transcriptional changes in gene expression and posttranscriptional regulation of various signal transduction pathways (19, 31) . A stepwise increase from static to flow conditions is known to induce an acute, short-term activation of proinflammatory pathways, including MCP-1 and tissue factor expression (32) (33) (34) . In contrast, long-term exposure of endothelial cells to shear, which more close-
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The ly resembles the in vivo conditions, suppresses gene expression of MCP-1 (32) . The present study extends these findings by demonstrating that preexposure of endothelial cells to shear stress for 12 hours prevents CD40L-induced MCP-1 and tissue factor expression. The inhibitory effect of shear stress appears to rely on the expression of TRAF-3. However, overexpression of dominant-negative TRAF-3 or TRAF-3 antisense oligonucleotides (data not shown) only partially reversed the inhibitory effect of shear stress, suggesting that additional shear stress-induced signaling pathways can compensate for the loss of TRAF-3. Shear-induced increases in nitric oxide synthesis (35, 36) may interfere with AP-1 activation by inhibition of JNK caused by Snitrosylation (37), or by direct interference with AP-1 binding activity (38) (39) (40) . However, inhibition of endothelial nitric oxide synthase by N G -mono-methyl-L-arginine did not reverse the inhibitory effect of shear stress in the presence of dominant-negative TRAF-3 (data not shown), implicating a nitric oxide-independent pathway. Another possibility might be that shear stress inhibits JNK activation through cross-talk among MAPK family members, as suggested recently by Surapisitchat and coworkers (41) , who demonstrated that TNF-α-induced JNK activation is inhibited by shear stress-induced activation of ERK1/2. Consistent with these findings, shear stress was also shown to block JNK activation via inhibition of the MAPK kinase kinase apoptosis signal-regulating kinase 1 (ASK-1) (42). Of note, both of these studies investigated shortterm effects of shear stress (10 minutes), whereas in the present study, cells were continuously preexposed to shear stress for 12 hours. This may explain why we did not find a direct inhibition of CD40-stimulated JNK activity, but an inhibition of the CD40-induced gene expression caused by increased expression of TRAF-3 after long-term exposure of endothelial cells to flow. The remaining TRAF-3-independent inhibition of CD40L-induced endothelial activation by prolonged flow exposure requires further elucidation.
Although inhibition of TRAF-3 only partially reversed the protective effect of shear stress, TRAF-3 overexpression prevented CD40L-induced MCP-1 expression, suggesting that TRAF-3 is sufficient to block CD40 signaling. TRAF-3 seems to interfere with CD40 signaling by inhibiting AP-1 DNA-binding activity. This is surprising, taking into account that a yeast two-hybrid screen identified TRAF-3 as a CD40 receptor-binding protein (27) . However, immunohistochemistry and biochemical fractionation clearly revealed different localization of TRAF-3 in endothelial cells than in NIH 3T3 cells, with TRAF-3 being localized mainly in the nuclei of endothelial cells. In addition, no interaction of TRAF-3 with the CD40 receptor was detectable in coimmunoprecipitation studies (data not shown). Interestingly, TRAF-3 is the only protein within the TRAF superfamily that contains a basic leucine zipper motif at amino acid position 287-342 (27) . Given that proteins with a basic leucine zipper readily form homo-or heterodimers, and thereby provide a diversity of transcription factor complexes to inhibit or activate gene expression (29) , one might speculate that TRAF-3 acts by interacting with AP-1 complex formation.
Shear stress specifically upregulates TRAF-3 expression, whereas TRAF-2 and TRAF-5 were not affected by exposure to shear stress. The question remains how shear stress increases TRAF-3 expression. Shear stress can activate a variety of different transcription factors, including SP-1, AP-1 (c-Jun/c-Fos), and NF-κB (19, 43) . However, TRAF-3 transcription was essentially unchanged after exposure to shear stress, as determined by nuclear run-on assay. These data suggest that shear stress stabilizes TRAF-3 mRNA and thereby augments TRAF-3 expression. Dissection of the molecular pathways involved in TRAF-3 stabilization requires further investigation.
In conclusion, the data of the present study suggest that selective upregulation of TRAF-3 by shear stress may provide a novel anti-inflammatory and anticoagulatory strategy to protect the endothelium.
